Arkansas wine

Overview of Aplaviroc, an investigational drug

Engineered Monoclonal Antibodies

Diagram of engineered monoclonal antibodies

Engineered monoclonal antibodies are a class of biological therapies that are designed to target specific antigens on the surface of cells. These antibodies are produced using recombinant DNA technologies and are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Structure and Function

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule. The tips of the "Y" contain the antigen-binding sites, which are highly specific to the target antigen. This specificity allows monoclonal antibodies to bind to their target with high affinity, blocking or modulating the function of the antigen.

Types of Engineered Monoclonal Antibodies

There are several types of engineered monoclonal antibodies, each designed for specific therapeutic purposes:

• Chimeric antibodies: These antibodies are composed of murine (mouse) variable regions and human constant regions. They are less immunogenic than fully murine antibodies.

• Humanized antibodies: These antibodies are mostly human, with only the antigen-binding sites derived from murine sources. This reduces the risk of immune reactions.

• Fully human antibodies: These are entirely human in origin, produced using transgenic mice or phage display technologies.

• Bispecific antibodies: These antibodies are engineered to bind two different antigens simultaneously, offering unique therapeutic mechanisms.

Applications in Medicine

Engineered monoclonal antibodies have revolutionized the treatment of many diseases:

• Cancer therapy: Monoclonal antibodies can target specific tumor antigens, leading to direct tumor cell killing or recruitment of immune cells to attack the tumor.

• Autoimmune diseases: By targeting specific components of the immune system, monoclonal antibodies can reduce inflammation and tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.

• Infectious diseases: Monoclonal antibodies can neutralize pathogens or their toxins, providing passive immunity or enhancing the host's immune response.

Production

The production of engineered monoclonal antibodies involves several steps:

1. Antigen identification: The target antigen is identified and characterized. 2. Hybridoma technology: B cells from immunized animals are fused with myeloma cells to create hybridomas that produce the desired antibody. 3. Recombinant DNA technology: Genes encoding the antibody are cloned and expressed in suitable host cells, such as Chinese hamster ovary cells. 4. Purification and formulation: The antibodies are purified and formulated for clinical use.

Challenges and Future Directions

While engineered monoclonal antibodies have shown great promise, there are challenges such as high production costs, potential for immune reactions, and the development of resistance. Ongoing research aims to improve antibody design, reduce immunogenicity, and enhance therapeutic efficacy.

Related Pages

• Monoclonal antibody therapy
• Biopharmaceutical
• Immunotherapy
• Hybridoma technology

Aplaviroc is an investigational drug that was developed as a potential treatment for HIV/AIDS. It belongs to a class of drugs known as CCR5 receptor antagonists, which are designed to block the CCR5 receptor on the surface of T cells, preventing the HIV virus from entering these cells and replicating.

Mechanism of Action

Aplaviroc functions by selectively binding to the CCR5 receptor, a co-receptor that HIV uses to enter CD4+ T cells. By blocking this receptor, aplaviroc prevents the virus from attaching to and entering the host cells, thereby inhibiting its replication cycle. This mechanism is similar to other CCR5 antagonists, such as maraviroc, which are used in the treatment of HIV.

Development and Clinical Trials

Aplaviroc was developed by GlaxoSmithKline and underwent several phases of clinical trials. During these trials, the drug was evaluated for its efficacy in reducing viral load in patients with HIV, as well as its safety and tolerability. However, the development of aplaviroc was halted due to concerns about liver toxicity observed in some patients during the trials.

Pharmacokinetics

The pharmacokinetic profile of aplaviroc includes its absorption, distribution, metabolism, and excretion. Aplaviroc is administered orally and is absorbed into the bloodstream, where it exerts its effects on the CCR5 receptor. The drug is metabolized primarily in the liver and excreted through the kidneys.

Potential Side Effects

While aplaviroc showed promise in early trials, its development was discontinued due to adverse effects, particularly hepatotoxicity. Other potential side effects observed in clinical trials included gastrointestinal disturbances, headache, and dizziness. The risk of liver damage was a significant concern, leading to the cessation of further development.

Current Status

As of now, aplaviroc is not approved for use in any country, and its development has been discontinued. Research into CCR5 antagonists continues, with other drugs in this class being used in clinical practice.

Related Pages

• HIV/AIDS
• CCR5 receptor antagonist
• Maraviroc
• GlaxoSmithKline

Gallery

• 

  Chemical structure of Aplaviroc

• 

  Map of Arkansas

• 

  Arkansas Quality Wine Competition